BOULDER, Colo., August 18, 2026
Enveda announced positive Phase 1 results for ENV-308, an investigational oral medicine designed from the chemistry of exercise and being developed as a potential treatment to support long-term metabolic health. The company reported that the study demonstrated a favorable safety and tolerability profile across 88 healthy adult volunteers, supporting continued clinical development of ENV-308. The program is particularly focused on the growing challenge of maintaining weight and metabolic benefits after discontinuation of GLP-1 therapies. Enveda plans to advance ENV-308 into additional clinical studies, including a planned Phase 2 program designed to evaluate whether the investigational medicine can help people maintain weight loss after stopping GLP-1 treatment.
ENV-308 Advances Exercise-Inspired Drug Development
ENV-308 is designed to mimic Lac-Phe, a naturally occurring molecule released by the body following intense exercise and also after meals. Enveda discovered and developed ENV-308 using its proprietary AI-powered PRISM platform, which is designed to identify biologically active molecules and translate insights from natural chemistry into potential medicines. Lac-Phe has attracted significant scientific interest because preclinical research has linked the molecule to appetite regulation and metabolic effects associated with exercise. However, naturally occurring Lac-Phe has properties that limit its development as a conventional medicine, including rapid clearance from the body. Enveda engineered ENV-308 as a daily oral small molecule intended to reproduce relevant biological effects while providing drug-like properties suitable for clinical development. The company is positioning the program around a broader approach to metabolic health rather than focusing solely on short-term weight reduction.
Phase 1 Study Shows Favorable Safety Profile
The first-in-human Phase 1 clinical trial evaluated ENV-308 across 88 healthy volunteers, primarily assessing safety, tolerability and pharmacokinetics. According to Enveda, participants tolerated the investigational medicine well across the evaluated dose range, with no serious adverse events, treatment discontinuations or dose interruptions reported. The company particularly highlighted the gastrointestinal safety profile, given that nausea, vomiting and related gastrointestinal effects can contribute to discontinuation of existing weight-loss medicines. The study also evaluated the effect of ENV-308 on circulating leptin, a hormone involved in appetite regulation and energy balance. Enveda reported reductions in circulating leptin, with the largest reductions observed among participants who had higher baseline leptin levels relative to sex. The company said this exploratory finding provides an early biological signal that ENV-308 is engaging pathways relevant to metabolic disease, although the Phase 1 study was conducted in healthy volunteers and was not designed to establish weight-loss efficacy.
Advertisement
Enveda Plans Phase 2 Testing for Weight Maintenance
The next stage of development will focus on whether ENV-308 can translate its early safety and biological findings into meaningful metabolic benefits in patients. Enveda plans to evaluate the medicine in people who have discontinued or are preparing to discontinue GLP-1 therapy, with the objective of determining whether ENV-308 can help maintain weight loss and other metabolic improvements following treatment withdrawal. In preclinical studies, ENV-308 reportedly preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. The company is also investigating whether the compound could potentially complement GLP-1 medicines or support different dosing strategies, but these observations remain preclinical and require validation in human trials. Enveda is additionally evaluating ENV-308 for other conditions in which exercise-associated biological effects may have therapeutic relevance, including migraine, inflammatory bowel disease and polyendocrine metabolic ovarian syndrome. The Phase 1 results therefore provide an early clinical foundation for a broader development strategy centered on translating the biology of exercise into medicines.
Source: Enveda press relese
